Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol and Etodolac in Pancreatic Cancer Surgery
NCT03838029Phase 2Recruiting
- Sponsor
- Shamir Medical Center
- Start
- Nov 2019
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic cancer (PC) comparing Propranolol and Etodolac with Placebo (2 arms). Primary endpoints: Disease-Free Survival at 1 year, Overall Survival at 5 years and 2 more. Started Nov 2019; status: recruiting.
02
Drugs
propranololetodolac
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03838029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838029.